» Articles » PMID: 33151906

50th Anniversary of the First Clinical Trial with ICI 46,474 (tamoxifen): then What Happened?

Overview
Specialties Endocrinology
Oncology
Date 2020 Nov 5
PMID 33151906
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Following the discovery and approval of the oral contraceptive, the pharmaceutical industry sought new opportunities for the regulation of reproduction. The discovery of the first non-steroidal anti-oestrogen MER25, with antifertility properties in laboratory animals, started a search for 'morning-after pills'. There were multiple options in the 1960s, however, one compound ICI 46,474 was investigated, but found to induce ovulation in subfertile women. A second option was to treat stage IV breast cancer. Although the patent for ICI 46,474 was awarded in the early 1960s in the UK and around the world, a patent in the USA was denied on the basis that the claims for breast cancer treatment were not supported by evidence. A trial at the Christie Hospital and Holt Radium Institute in Manchester, published in 1971, showed activity compared with alternatives: high-dose oestrogen or androgen treatment, but the US Patent Office was unswayed until 1985! The future of tamoxifen to be, was in the balance in 1972 but the project went forward as an orphan drug looking for applications and a translational research strategy was needed. Today, tamoxifen is known as the first targeted therapy in cancer with successful applications to treat all stages of breast cancer, male breast cancer, and the first medicine for the reduction of breast cancer incidence in high-risk pre- and post-menopausal women. This is the unlikely story of how an orphan medicine changed medical practice around the world, with millions of women's lives extended.

Citing Articles

Basic, translational, and clinical research - a short reflection.

Kopp P Arch Endocrinol Metab. 2025; 68(Spec Issue):e240400.

PMID: 39876966 PMC: 11771749. DOI: 10.20945/2359-4292-2024-0400.


Utilisation of endocrine therapy for cancer in Indigenous peoples: a systematic review and meta-analysis.

Bizuayehu H, Belachew S, Jahan S, Diaz A, Baxi S, Griffiths K BMC Cancer. 2024; 24(1):882.

PMID: 39039483 PMC: 11264465. DOI: 10.1186/s12885-024-12627-6.


Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.

Hancock G, Gertz J, Jeselsohn R, Fanning S Endocrinology. 2024; 165(6).

PMID: 38643482 PMC: 11075793. DOI: 10.1210/endocr/bqae051.


Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?.

Buijs S, Koolen S, Mathijssen R, Jager A Drugs. 2024; 84(4):385-401.

PMID: 38480629 PMC: 11101371. DOI: 10.1007/s40265-024-02010-x.


Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.

Scherbakov A, Sorokin D, Razuvaeva V, Shchegolev Y, Andreeva O, Salnikova D Biomed Rep. 2024; 20(3):42.

PMID: 38343657 PMC: 10853760. DOI: 10.3892/br.2024.1727.


References
1.
Jordan V, Fenuik L, Allen K, Cotton R, Richardson D, WALPOLE A . Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens. Eur J Cancer (1965). 1981; 17(2):193-200. DOI: 10.1016/0014-2964(81)90036-0. View

2.
Jordan V . Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006; 147 Suppl 1:S269-76. PMC: 1760730. DOI: 10.1038/sj.bjp.0706399. View

3.
Cuzick J, Baum M . Tamoxifen and contralateral breast cancer. Lancet. 1985; 2(8449):282. DOI: 10.1016/s0140-6736(85)90338-1. View

4.
Lippman M, Bolan G . Oestrogen-responsive human breast cancer in long term tissue culture. Nature. 1975; 256(5518):592-3. DOI: 10.1038/256592a0. View

5.
HOLTKAMP D, GRESLIN J, ROOT C, LERNER L . Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proc Soc Exp Biol Med. 1960; 105:197-201. DOI: 10.3181/00379727-105-26054. View